SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a severe sell-off following the collapse of a key relationship with Marvell, which terminated purchase orders citing a confidentiality breach by management. The community is sharply divided between investors calling for a total leadership overhaul due to the perceived communication failures and those attempting to justify the drop as an overreaction that creates a long-term buying opportunity.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it breaks into new all-time high territory, with the community largely focused on the stock's massive institutional momentum and its role as the centerpiece of the ongoing AI infrastructure supercycle. While many investors are celebrating the breakout and discussing aggressive new price targets, others are debating the sustainability of the rally, noting potential divergences in market breadth and questioning the long-term impact of extreme valuations.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. It operates through the following segments: Seed and Integrated Products, Crop Protection, Crop Nutrition, and Emerging Solutions. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science SA is trending due to significant retail interest surrounding its low-float status, which market participants are actively discussing as a primary catalyst for potential short-squeeze activity. The community is sharply divided, with bulls pointing to the company's molecular farming technology as a long-term play, while bears express skepticism regarding its underlying financials and the risk of being left as 'exit liquidity' in what they label a pump-and-dump scheme.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as investors react to successful demonstration flights in New York City and ongoing FAA certification progress, signaling a shift from concept to real-world deployment. While the community is actively debating the stock's long-term execution risk and potential for volatility, many see the recent milestones as a critical step toward the company's 2026 commercial launch goals.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors monitor high short interest and limited share availability, which supporters believe sets the stage for a significant short squeeze. Sentiment is bolstered by the pending Northern Data acquisition and strategic partnerships with Tether, leading the community to discuss its potential as a long-term AI and cloud infrastructure play.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is seeing heightened activity as investors weigh recent reports of revenue growth and operational improvements against ongoing concerns about cash burn and a challenging retail environment. The community remains deeply divided, with some traders focused on potential squeeze setups and the company's long-term turnaround strategy, while others emphasize the stock's significant decline and persistent volatility.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is experiencing extreme volatility and intense community speculation following a parabolic run that has driven significant short-squeeze discussions. Investors are actively debating the sustainability of this momentum, with many highlighting the stock's low float and the ongoing battle between aggressive buying and short-selling interest.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is experiencing significant volatility and trading volume as investors react to bullish institutional accumulation and ongoing speculation regarding potential buyout interest or strategic partnerships for its lead asset, paridiprubart. Community discussions remain polarized between optimistic longs betting on a major acquisition or regulatory breakthrough and vocal skeptics highlighting historical trial delays and the potential for share dilution.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is trending due to significant trading volume and momentum, with the community actively debating whether the recent price action indicates a sustained breakout or another pump-and-dump cycle. Traders are closely monitoring the token's circulating supply and potential for short squeezes while discussing its role within the broader Solana DeFi ecosystem.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is facing downward pressure as investors react to conservative full-year guidance and concerns surrounding the upcoming transition of its lead product, DefenCath, away from its initial reimbursement status. Despite strong recent revenue and a newly authorized share buyback program, the community remains divided, with long-term holders highlighting the stock's low valuation relative to its pipeline potential and upcoming Phase III trial data for Rezzayo.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up  Following Analyst Upgrade

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade...

Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Barclays

Barclays raised shares of Celldex Therapeutics from an "underweight" rating to an "overweight" rating and set a $45.00 price target for the company in a report on Monday...

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High - Here's What Happened

Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week High - Time to Buy...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve analysts that are currently covering the firm, Marketbeat.com...

Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX

Tudor Investment Corp ET AL purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 31,618 shares of the biopharmaceutical company's stock...

Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment

Celldex Therapeutics (NASDAQ:CLDX) executives used an appearance at H.C. Wainwright's annual Inflammation and Skin Disease Conference to highlight the company's late-stage plans for barzolvolimab, an...

Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume  - Here's Why

Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading Volume - Here's Why...

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?

Celldex Therapeutics (NASDAQ:CLDX) Shares Cross Above 200-Day Moving Average - Time to Sell...

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year High Following Analyst Upgrade

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month High Following Analyst Upgrade...

Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Wolfe Research

Wolfe Research raised shares of Celldex Therapeutics from a "peer perform" rating to an "outperform" rating and set a $44.00 price objective on the stock in a research report on Monday...

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CLDX News

CLDXCelldex Therapeutics Inc.